European Society of Cardiology

European Society of Cardiology

Perspective from B. Hadley Wilson, MD, FACC
September 01, 2019
7 min read
Save

Complete revascularization superior to culprit lesion-only PCI for STEMI, multivessel CAD: COMPLETE

Perspective from B. Hadley Wilson, MD, FACC
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Shamir R. Mehta

PARIS — Complete revascularization was superior to culprit lesion-only PCI for reducing risk for CV death or MI in patients with STEMI and multivessel CAD, according to results from the COMPLETE trial presented at the European Society of Cardiology Congress.

“For the first time, we have clear evidence that a complete revascularization strategy reduces hard clinical outcomes,” Shamir R. Mehta, MD, professor in the division of cardiology at McMaster University in Hamilton, Ontario, Canada, director of interventional cardiology at Hamilton Health Services and principal investigator of the COMPLETE trial, told Cardiology Today. “We have evidence previously that it reduced revascularization, but that’s a soft outcome. In an open-label trial where the patient and physician know the treatment arm, it has less weight. What we really wanted to know was whether a nonculprit lesion PCI can change the natural history of the disease. Now we have that. We have that evidence for the first time. So yes, this will change clinical practice, and yes, this will change the guidelines because the results are definitive.”

Patents with STEMI

In the multinational, randomized trial, researchers analyzed data from 4,041 patients who presented to the hospital with STEMI and were able to undergo randomization with 72 hours after successful culprit lesion PCI. Patients also had multivessel CAD, which was defined as the presence of at least one nonculprit lesion that was angiographically significant and was amenable to PCI and within a vessel at least 2.5 mm in diameter not stented during the index culprit lesion PCI.

“The baseline characteristics are very compatible to the STEMI patient population,” Mehta said during the press conference.

Complete revascularization was superior to culprit lesion-only PCI for reducing risk for CV death or MI in patients with STEMI and multivessel CAD, according to results from the COMPLETE trial presented at the European Society of Cardiology Congress.
Source: Adobe Stock

Patients were assigned either complete (n = 2,016; mean age, 62 years; 81% men) or culprit lesion-only revascularization (n = 2,025; mean age, 62 years; 79% men).

“An important caveat of the design of this trial was that investigators were asked before randomization when they intended to perform their nonculprit lesion PCI: early during the initial hospitalization or after discharge from hospital,” Mehta said during the press conference.

Both groups received guideline-based medical therapy, which included dual antiplatelet therapy with ticagrelor (Brilinta, AstraZeneca) and aspirin for a least 1 year, followed by aspirin for all patients and 60 mg of ticagrelor twice per day for those who did not have a high risk for bleeding. Other recommended therapies included ACE inhibitors, high-dose statin therapy, angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists.

PAGE BREAK

The first coprimary outcome was a composite of CV death or new MI. The second coprimary outcome was a composite of CV death, ischemia-driven revascularization or new MI. Safety outcomes were defined as contrast-associated acute kidney injury and major bleeding. Follow-up was conducted at 6 weeks, 6 months, 1 year and annually.

“The nonculprit lesion was located in the [left anterior descending artery] in approximately 40% of cases and in the proximal LAD in approximately 10% of cases,” Mehta said during the press conference. “Probably one of the most important parameters in the trial is that complete revascularization was actually achieved in over 90% of patients who are allocated to the nonculprit lesion PCI arm. That means that they had a SYNTAX score of 0, so there was no significant disease left behind in that group.”

Results from this trial were also published in The New England Journal of Medicine.

Events during follow-up

CV death or new MI occurred in 7.8% of patients in the complete revascularization group compared with 10.5% of those in the culprit-lesion-only PCI group at a median follow-up of 3 years (HR = 0.74; 95% CI, 0.6-0.91). The number needed to treat to prevent one of these events over a 3-year period was 37.

The second coprimary outcome occurred in 8.9% of patients assigned complete revascularization compared with 16.7% of those assigned culprit lesion-only PCI (HR = 0.51; 95% CI, 0.43-0.61).

“The complete revascularization strategy has an effect over long-term events similar to what we’ve seen with CABG surgery 20 years ago with medical management,” Mehta said during the press conference.

The researchers found that the benefit conferred from complete revascularization was consistent regardless of the timing of nonculprit-lesion PCI (P for interaction for the first coprimary outcome = .62; P for interaction for the second coprimary outcome = .27).

“There is absolutely no interaction, meaning that it doesn’t matter whether it is performed early during the index hospitalization or later after discharge from hospital,” Mehta said during the press conference. “The benefits on hard outcomes, CV death or MI are preserved, and the reason for that likely is because the benefits of complete revascularization occur over the long term.”

The safety outcomes did not differ between the groups.

Mehta said clear evidence from this trial may be enough to prove that complete revascularization benefits these patients, but there is some potential for further research.

PAGE BREAK

“If there is more research, they’ll just tweak the question as to is it safe to do it during an index PCI procedure, although our data suggest that the timing during the first month to a month and a half is probably not that important because the main benefit occurs late over the long term,” Mehta told Healio.

This trial confirms how cardiologists should treat this specific patient population.

Roxana Mehran

“It’s a groundbreaking study, that complete revascularization should be the way to go with all of our STEMI patients,” Cardiology Today’s Intervention Associate Medical Editor Roxana Mehran, MD, FACC, FAHA, FESC, professor of medicine at Icahn School of Medicine at Mount Sinai, said in an interview. “We can do it either immediately or out of hospital. Timing doesn’t matter. We just have to give blood supply to the entire coronary tree and to all of the myocardium, not just to the culprit artery. To me, it’s a no-brainer.”

Thomas Engstrøm

“In light of the results of the well-planned and well-executed trial by Mehta [and colleagues], the guidelines should recommend a strategy of full revascularization in patients with STEMI and multivessel disease, at least in those who have suitable nonculprit lesions,” Lars Køber, MD, clinical professor in the department of clinical medicine at Rigshospitalet University in Copenhagen, and Thomas Engstrøm, MD, associate professor at Rigshospitalet University, wrote in a related editorial in NEJM. – by Darlene Dobkowski

References:

Mehta MR, et al. Hot Line Session 1. Presented at: European Society of Cardiology Congress; Aug. 31-Sept. 4, 2019; Paris.

Køber L, et al. N Engl J Med. 2019;doi:10.1056/NEJMe1910898.

Mehta MR, et al. N Engl J Med. 2019;doi:10.1056/NEJMoa1907775.

Disclosures: Mehta reports he received grants from AstraZeneca and Boston Scientific and other support from AstraZeneca. Mehran reports she was on the executive committee for the COMPLETE trial. Køber reports he received personal fees from Bristol-Myers Squibb and Novartis and grant and other support from AstraZeneca. Engstrøm reports he received personal fees from Abbott, AstraZeneca, Bayer and Bristol-Myers Squibb. Please see the study for all other authors’ relevant financial disclosures.